Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Surufatinib - HUTCHMED

Drug Profile

Surufatinib - HUTCHMED

Alternative Names: HMPL-012; Sufatinib; Sulanda; Sulfatinib - HUTCHMED

Latest Information Update: 21 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer Fujian Cancer Hospital; Hutchison MediPharma; HUTCHMED
  • Class Antineoplastics; Indoles; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuroendocrine tumours
  • Phase II/III Biliary cancer; Pancreatic cancer
  • Phase II Colorectal cancer; Small cell lung cancer; Solid tumours; Thyroid cancer
  • Phase I/II Soft tissue sarcoma

Most Recent Events

  • 08 May 2024 Phase-II/III clinical trials in Pancreatic cancer (Metastatic disease, Combination therapy, Late-stage disease, First-line therapy) in China (PO) (NCT06361888)
  • 12 Apr 2024 Hutchmed plans a phase II/III for Pancreatic cancer (Combination therapy, Metastatic disease, First-line therapy, Late-stage disease) in China in May 2024 (NCT06361888)
  • 31 Jul 2023 HUTCHMED decides not to submit NDA for Neuroendocrine tumour post discussion with PMDA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top